Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign In
  • Home
  • World
    Sections
    • World Home
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Meta donates $1mn to Trump’s inauguration fund
    • Nato’s European members discuss 3% target for defence spending
    • James Dyson is right to fight for British strawberries
    • Demand for UK rented properties falls for first time since pandemic
    • Romania and Bulgaria to join EU’s Schengen free movement area
  • US
    Sections
    • US Home
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
    Most Read
    • Meta donates $1mn to Trump’s inauguration fund
    • Nato’s European members discuss 3% target for defence spending
    • Luxury real estate brokers charged with sex trafficking
    • Dollar’s surge sparks biggest fall in emerging market currencies in 2 years
    • The western myth of the ‘guy we can do business with’
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Meta donates $1mn to Trump’s inauguration fund
    • James Dyson is right to fight for British strawberries
    • Selfridges’ Thai co-owner says it overpaid for luxury store portfolio
    • Luxury real estate brokers charged with sex trafficking
    • Demand for UK rented properties falls for first time since pandemic
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • Meta donates $1mn to Trump’s inauguration fund
    • The AI agents are coming
    • Romania’s cancelled election is a lesson in social media manipulation
    • Australia to introduce ‘news tax’ on tech companies
    • Google races to bring AI-powered ‘agents’ to consumers
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • Former BP chief Looney joins board of Abu Dhabi energy group XRG
    • Dollar’s surge sparks biggest fall in emerging market currencies in 2 years
    • The astonishing success of Eurozone bailouts
    • Not too hot is a weak justification for a cut
    • UK fintech Stenn collapsed after Russia money laundering case drew scrutiny
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • James Dyson is right to fight for British strawberries
    • The western myth of the ‘guy we can do business with’
    • Romania’s cancelled election is a lesson in social media manipulation
    • The astonishing success of Eurozone bailouts
    • The AI agents are coming
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • Nasdaq’s board diversity rules struck down by US court
    • Why business should not ape football when it comes to pay
    • Pay UK bosses like football stars, says Lord Spencer
    • Winner Parmy Olson on AI: ‘It’s not uncontrollable’
    • Obsessed with: Vancouver’s top-quality — and inexpensive — sushi
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Mitch McConnell: ‘We’re in a very, very dangerous world right now’
    • Pat Boonnitipat expected to lose money on his debut film. It’s become an Asian cultural supernova
    • It’s party season — let the covert interiors appraisals begin
    • Murder at the Castle — Miss Merkel finds her freedom
    • Recipe Club: Bob Bob Ricard’s chicken and champagne pie
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

AstraZeneca PLC

  • Thursday, 11 April, 2024
    AstraZeneca shareholders approve CEO Soriot’s £18.7mn pay despite revolt

    Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss

    Pascal Soriot
  • Tuesday, 9 April, 2024
    Executive Pay
    AstraZeneca’s Soriot ‘massively underpaid’ at £16.9mn, says top shareholder

    GQG Partners argues that pharma group has performed strongly under long-serving chief

    AstraZeneca chief Pascal Soriot
  • Monday, 1 April, 2024
    Lex
    A decade after Pfizer, AstraZeneca needs to find its growth again

    UK pharma group’s chief has a fresh challenge — persuading investors that its best days are not behind it

    Pascal Soriot
  • Saturday, 30 March, 2024
    AstraZeneca shareholders urged to oppose pay plan for CEO Soriot

    Shareholder advisory groups say potential £18.7mn payout is excessive

    Pascal Soriot
  • Tuesday, 19 March, 2024
    AstraZeneca strikes $2.4bn deal for radiotherapy biotech Fusion

    Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care

    AstraZeneca logo
  • Friday, 23 February, 2024
    European equities
    Europe’s ‘Granolas’ fuel record stock market surge

    Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’

    A montage showing a Wegovy injection dose, the ASML logo and luxury products, including nail polish and a handbag, against two chart lines
  • Monday, 19 February, 2024
    AstraZeneca unveils successes in treatment of lung cancer

    Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage

    AstraZeneca’s logo outside its offices in Hamburg, Germany
  • Thursday, 8 February, 2024
    New drug launches weigh on AstraZeneca profits

    Annual earnings at Anglo-Swedish pharma group miss expectations but revenues rise to $45.8bn

    Test tubes being filled in front of an AstraZeneca logo
  • Wednesday, 31 January, 2024
    AstraZeneca wrongfully dismissed senior scientist, tribunal finds

    James Muir was discriminated against on the basis of his mental health disability

    Astrazeneca logo on a building
  • Wednesday, 24 January, 2024
    UK manufacturing
    UK government eyes AstraZeneca factory expansion deal

    State aid package worth tens of millions of pounds expected as part of any agreement

    AstraZeneca’s plant in Speke near Liverpool
  • Tuesday, 26 December, 2023
    AstraZeneca set to make one of its first acquisitions in China

    Gracell Biotechnologies would operate as wholly owned subsidiary under terms of deal

    The AstraZeneca name and logo at an exposition in Shanghai
  • Tuesday, 12 December, 2023
    AstraZeneca strikes $1bn deal to acquire its first vaccine company

    Anglo-Swedish pharma group agrees to buy Seattle-based biotech Icosavax

    The AstraZeneca logo pictured on a building
  • Sunday, 3 December, 2023
    AstraZeneca ties up with AI biologics company to develop cancer drug

    Deal with Absci is the latest between big pharma and tech companies to build new disease treatments

    Three DNA Damage Response enzymes repair single stranded DNA breaks
  • Friday, 1 December, 2023
    Investments
    Directors’ Deals: Strategy refresh spurs Unilever directors

    Group plans to refocus on 30 core brands

    Unilever chief executive Hein Schumacher
  • Wednesday, 22 November, 2023
    AstraZeneca fights accusations its Covid-19 jab was ‘defective’

    Vaccine recipient claims he suffered side effect of severe blood clot

    A health worker prepares a dose of the AstraZeneca Covid-19 vaccine
  • Thursday, 9 November, 2023
    AstraZeneca signs deal for oral obesity drug and lifts profit outlook

    Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs

    An AstraZeneca facility in Sweden
  • Monday, 23 October, 2023
    AstraZeneca hails ‘clinically meaningful’ cancer drug trial results

    Drugmaker upbeat on full data after initial findings disappointed investors

    AstraZeneca logo on its building in Macclesfield, England
  • Tuesday, 3 October, 2023
    AstraZeneca settles heartburn drug lawsuits for $425mn

    Drugmaker says settlements will avoid costly litigation but claims are ‘without merit’

    AstraZeneca logo on a building in Macclesfield, England
  • Friday, 25 August, 2023
    AstraZeneca sues US government over drug price reforms

    Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines

    Assembly line at AstraZeneca manufacturing plant
  • Wednesday, 9 August, 2023
    AstraZeneca signs vaccine deal with China’s CanSino

    Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is ‘high unmet need’

    AstraZeneca’s site in Macclesfield, UK
  • Friday, 28 July, 2023
    AstraZeneca beats estimates with strong cancer and diabetes drug sales

    Drugmaker reports 38% jump in earnings as it expands genomic medicine business

    A laboratory worker takes a reading
  • Monday, 3 July, 2023
    AstraZeneca shares fall after cancer drug trial disappoints investors

    Trial studied patients with advanced non-small cell lung cancer

    Delivery workers ride motorcycles past an AstraZeneca research and development facility in Shanghai
  • Monday, 19 June, 2023
    LexPharmaceuticals sector
    AstraZeneca/China: break-up deal would reflect necessity not choice Premium content

    Move highlights growing trend by businesses to insulate themselves from the region’s geopolitics

    A view of the corporate logo of the pharmaceutical company Astrazeneca at its new headquarters in Hamburg
  • Monday, 19 June, 2023
    FT News Briefing podcast8 min listen
    Astrazeneca could spin off China business

    France is challenging a German-led plan to build up Europe’s air defences

  • Sunday, 18 June, 2023
    Chinese business & finance
    AstraZeneca drafts plan to spin off China business amid tensions

    Anglo-Swedish drugmaker views listing a separate unit in Hong Kong as potential shelter from global strife

    Photo of lab work at AstraZeneca China
Previous page You are on page 2 Next page

Join us at an FT Live event

Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

FT Live
US Pharma and Biotech Summit
How the new market cycle will finance the next period of investing in innovation
Thursday, 15 May 2025New York, NY, USA
Explore all events

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareersSuppliers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT Live EventsFT ForumsBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:International
UK
Subscribe for full access

Top sections

  • Home
  • World
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • US
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Schools
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In